StockNews.AI
RVNC
StockNews.AI
193 days

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 4, 2025 in Revance Lawsuit - RVNC

1. Revance Therapeutics faces a class action lawsuit over alleged securities fraud. 2. The lawsuit pertains to events from February 29, 2024, to December 6, 2024. 3. Claims include breach of distribution agreements impacting Revance's market activities. 4. Investors may seek compensation without upfront costs or obligations. 5. Levi & Korsinsky has a strong track record in securities litigation.

4m saved
Insight
Article

FAQ

Why Bearish?

Legal issues can typically decrease investor confidence and market performance. Past cases show stocks often struggle after similar lawsuits are filed.

How important is it?

The lawsuit addresses potential fraud, directly impacting RVNC's viability and investor trust. Market reactions typically reflect legal proceedings in related companies.

Why Short Term?

Immediate legal challenges may impact RVNC's stock in the coming months. Momentum often stabilizes once legal uncertainties are resolved.

Related Companies

NEW YORK, Feb. 7, 2025 /PRNewswire/ --

Levi & Korsinsky, LLP notifies investors in Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ: RVNC) of a class action securities lawsuit.

CLASS DEFINITION:

The lawsuit seeks to recover losses on behalf of Revance investors who were adversely affected by alleged securities fraud between February 29, 2024 and December 6, 2024. Follow the link below to get more information and be contacted by a member of our team:

https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=127523&wire=4

RVNC investors may also contact Joseph E. Levi, Esq. via email at email@example.com or by telephone at (212) 363-7500.

CASE DETAILS:

The filed complaint alleges that defendants made false statements and/or concealed that: (i) Revance was in material breach of the Distribution Agreement with Teoxane, which granted Revance "the exclusive right to import, market, promote, sell and distribute Teoxane's line of dermal fillers; (ii) the foregoing subjected the Company to an increased risk of litigation, as well as monetary and reputational harm; (iii) all the foregoing increased the risk that the tender offer would be delayed and/or amended; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

WHAT'S NEXT?

If you suffered a loss in Revance during the relevant time frame, you have until March 4, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

NO COST TO YOU:

If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY:

Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
email@example.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE Levi & Korsinsky, LLP

Related News